iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024 [Yahoo! Finance]
iTeos Presents EOS-984 Preclinical Data Demonstrating Restoration of T Cell Activity from Adenosine Suppression at the American Association for Cancer Research Annual Meeting 2024
iTeos Therapeutics, Inc. (NASDAQ: ITOS) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $18.00 price target on the stock, down previously from $25.00.
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates [Yahoo! Finance]
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors